-- One study, to determine whether the superior activity of the modified anti-CD20 human-mouse chimeric antibody exposed unexpected adverse activity that may not have been seen with the less cytotoxic unmodified antibody. The study determined that the increased target activity and cytotoxicity of DXL-modified anti-CD20 does not affect safety even at doses 100 times that normally required for efficacy.
"We have confirmed that the dose of maximally effective DXL-peptide conjugated anti-CD20 DXL625 retains the impressive safety historically seen with therapeutic anti-CD20 antibodies," Dr. Thomas Kindt, Chief Scientific Officer of InNexus.
-- The second study defined the ability to "program" self-binding properties into antibodies. These "self-binding" interactions were seen to effectively increase the binding strength between the antibody and the target antigen, as determined repeatedly by measurable kinetic changes.
InNexus' AACR presentations are titled, "A Novel High Avidity Anti-CD20 With Markedly Increased Cytotoxicity Shows No Systemic Toxicity In The Cynomolgus Monkey At A Dose 100-Fold Above The Anticipated Therapeutic Dose", (AACR# 1231) and "Oxidative Modification Of An Anti-CD20 Antibody Imparts Autophilic Binding Kinetics", (AACR# 1230). Posters and company representatives will also be available within the AACR Antibody and Antibody Targets Session from 1:00-5:00 PM on April 19th in Hall B-F, Poster Section 12. The posters will also be available via the InNexus website beginning April 19th.
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL antibodies utilize unique, novel and patente
|SOURCE InNexus Biotechnology Inc.|
Copyright©2009 PR Newswire.
All rights reserved